Naloxone Hydrochloride
Product Images NDC 67296-2050

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Naloxone Hydrochloride (NDC 67296-2050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (a) (2y2 Figure 1 (a))

A line graph showing naloxone plasma concentration (ng/mL) over time (hours postdose) for different naloxone administration methods and dosages: 2 mg one spray in one nostril, 4 mg one spray in each nostril, 4 mg one spray in one nostril with higher concentration, 8 mg one spray in each nostril, and 0.4 mg intramuscular injection. The graph compares the concentration profiles and decline over 6 hours.*

FDA Label Image

Figure 1 (b) (2y2 Figure 1 (b))

A line graph showing naloxone plasma concentration (ng/mL) over time (hours postdose) for various dosages and administration methods, including 2 mg, 4 mg, and 8 mg nasal sprays with different concentrations and nostril usage, as well as a 0.4 mg intramuscular injection. The graph compares the pharmacokinetics of these dosing methods within one hour after administration.*

FDA Label Image

Step 3 (2y2 Step 3)

An instructional illustration showing a hand holding a nasal spray device labeled with parts 'Nozzle' and 'Plunger.' The image highlights the proper grip position on the spray apparatus.*

FDA Label Image

Step 4 (2y2 Step 4)

Black and white instructional illustration showing a person administering a nasal spray by inserting the nozzle into the nostril of a reclining individual, with one hand supporting the head and the other operating the spray device.*

FDA Label Image

Step 5 (2y2 Step 5)

An instructional diagram showing hand positioning for using a nasal spray device. One hand holds the spray bottle with the nozzle inserted into the nostril, while the other hand presses the actuator to release the spray.*

FDA Label Image

Step 7 (2y2 Step 7)

An instructional black-and-white illustration showing a person in a recovery position. Labels indicate that the hand supports the head and the knee stops the body from rolling onto the stomach, demonstrating proper body positioning.*

FDA Label Image

Label (Quick Start Image)

NALOXONE HCl Nasal Spray 4 mg label showing dosage of 1 spray per device. The label indicates it is for nasal use only and contains 4 mg naloxone HCl in 0.1 mL spray. Storage instructions recommend below 77°F (25°C) with excursions up to 104°F (40°C). Label also cautions against freezing and excessive heat and directs users to the enclosed quick start guide. Manufactured by Padagis and distributed by RedPharm Drug.*

FDA Label Image

Carton Principle Display Panel (Carton Image 1)

The image shows detailed instructions for Naloxone HCl Nasal Spray 4 mg, including usage guidelines, warnings, and a quick start guide. It explains identifying opioid overdose signs, how to remove, peel, and hold the spray device, and dosage information for a two-pack containing two 4 mg doses. The labeler is Padagis.*

FDA Label Image

Carton Principle Display Panel Body (Carton Image 2)

NALOXONE HYDROCHLORIDE 4 mg intranasal spray packaging label. The label indicates two single doses per box intended for intranasal use. It includes usage directions with illustrations on how to insert the nozzle and administer the spray. The label lists storage instructions and warnings, a barcode, and distributor details for Padagis. The product is described as a nasal spray containing 4 mg naloxone HCl per 0.1 mL dose.*

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical structure of naloxone hydrochloride, showing its molecular arrangement including hydroxyl groups, a ketone group, and an ethylene side chain with an associated hydrochloride (HCl) moiety.*

FDA Label Image

Step 2 (Image 01)

An instructional line drawing depicting hands opening and peeling a blister pack or foil-sealed medication unit dose. The image visually demonstrates how to access the product inside the packaging.*

FDA Label Image

Serialization (Image 06)

A product label insert panel for NALOXONE HYDROCHLORIDE by RedPharm Drug, showing placeholder text fields for serial number (S/N), lot number, and expiration date (Exp).*

FDA Label Image

Step 1 (Quick Start Guide Step 1)

An instructional illustration showing a person kneeling beside another person lying down, performing an emergency procedure that appears to be rescue breathing or airway management, likely related to administration of naloxone hydrochloride.*

FDA Label Image

Step 2 Image 2 (Quick Start Guide Step 2 Image 2)

Instructional illustration showing how to use a nasal spray device. The first panel labels the nozzle and plunger on the device. The second panel depicts the device being inserted into a person's nostril. The third panel shows the plunger being pressed to spray the medication.*

FDA Label Image

Step 3 (Quick Start Guide Step 3)

Illustration showing a person lying in the recovery position with one hand supporting the head and one knee positioned to stop the body from rolling onto the stomach. The figure is used to demonstrate proper positioning for patient safety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.